{"log_id": 4600859809093927853, "direction": 0, "words_result_num": 55, "words_result": [{"probability": {"variance": 6.4e-05, "average": 0.996433, "min": 0.950521}, "location": {"width": 847, "top": 179, "height": 41, "left": 214}, "words": "尿素暂时性增加(0.8%)、瘙痒(0.7%)、暂时性、可逆性的神经功能障碍(意识障碍、感觉"}, {"probability": {"variance": 1.4e-05, "average": 0.997129, "min": 0.987841}, "location": {"width": 257, "top": 213, "height": 28, "left": 213}, "words": "异常、失味症)(0.7%)等"}, {"probability": {"variance": 0.002232, "average": 0.990884, "min": 0.700054}, "location": {"width": 799, "top": 245, "height": 40, "left": 258}, "words": "4.与达卡巴嗪联合应用时(参见药物的相互作用),观察到有极少发生的肺毒性(急性"}, {"probability": {"variance": 1e-06, "average": 0.999051, "min": 0.997174}, "location": {"width": 244, "top": 279, "height": 28, "left": 211}, "words": "成年人呼吸抑制综合症)"}, {"probability": {"variance": 6.9e-05, "average": 0.995795, "min": 0.979166}, "location": {"width": 102, "top": 312, "height": 28, "left": 216}, "words": "【禁忌症】"}, {"probability": {"variance": 0.003056, "average": 0.987144, "min": 0.64935}, "location": {"width": 800, "top": 345, "height": 42, "left": 252}, "words": "1.怀孕期及哺乳期妇女;2.禁用于合并使用黄热病疫苗和采用苯妥英作为预防治疗(见"}, {"probability": {"variance": 0.00082, "average": 0.991405, "min": 0.857184}, "location": {"width": 573, "top": 378, "height": 39, "left": 207}, "words": "药物的相互作用):3.本品通常不推荐与减毒活疫苗联合使用"}, {"probability": {"variance": 0, "average": 0.999703, "min": 0.998926}, "location": {"width": 121, "top": 414, "height": 26, "left": 215}, "words": "注意事项】"}, {"probability": {"variance": 0.047699, "average": 0.744546, "min": 0.526145}, "location": {"width": 50, "top": 414, "height": 34, "left": 780}, "words": "天津"}, {"probability": {"variance": 0.000793, "average": 0.992067, "min": 0.827211}, "location": {"width": 835, "top": 444, "height": 41, "left": 204}, "words": "1.不推荐将本品用于过去4周内接受过化疗(或6周内用过亚硝基脲类药物治疗)的患者"}, {"probability": {"variance": 0.003287, "average": 0.979425, "min": 0.635512}, "location": {"width": 803, "top": 478, "height": 38, "left": 248}, "words": "2.只有患者在血小板和/或粒细胞计数分别等于或大于100,00/m3和2,000/m3的情"}, {"probability": {"variance": 0, "average": 0.99952, "min": 0.998916}, "location": {"width": 180, "top": 511, "height": 27, "left": 205}, "words": "况才考虑使用本品"}, {"probability": {"variance": 0.006998, "average": 0.979953, "min": 0.519474}, "location": {"width": 802, "top": 542, "height": 40, "left": 248}, "words": "3.每次新给药前,均须进行血细胞计数,并根据血液学状态调整用药剂量。下表可作指"}, {"probability": {"variance": 0, "average": 0.999912, "min": 0.999912}, "location": {"width": 23, "top": 579, "height": 23, "left": 205}, "words": "导"}, {"probability": {"variance": 7e-05, "average": 0.993426, "min": 0.981624}, "location": {"width": 65, "top": 614, "height": 23, "left": 313}, "words": "血小板"}, {"probability": {"variance": 2e-06, "average": 0.998688, "min": 0.996679}, "location": {"width": 68, "top": 616, "height": 24, "left": 591}, "words": "粒细胞"}, {"probability": {"variance": 0.000333, "average": 0.99005, "min": 0.945773}, "location": {"width": 157, "top": 619, "height": 25, "left": 840}, "words": "给药剂量百分数%"}, {"probability": {"variance": 0.024617, "average": 0.937445, "min": 0.49452}, "location": {"width": 119, "top": 648, "height": 21, "left": 305}, "words": "N>100,000"}, {"probability": {"variance": 2.9e-05, "average": 0.989877, "min": 0.982334}, "location": {"width": 30, "top": 656, "height": 20, "left": 906}, "words": "00%"}, {"probability": {"variance": 0.012097, "average": 0.964703, "min": 0.554317}, "location": {"width": 215, "top": 680, "height": 27, "left": 253}, "words": "100,000≥N>80,00"}, {"probability": {"variance": 5e-06, "average": 0.996222, "min": 0.992953}, "location": {"width": 72, "top": 687, "height": 18, "left": 585}, "words": "000≥N"}, {"probability": {"variance": 1.3e-05, "average": 0.994678, "min": 0.991095}, "location": {"width": 33, "top": 688, "height": 19, "left": 706}, "words": "500"}, {"probability": {"variance": 0, "average": 0.999285, "min": 0.998949}, "location": {"width": 23, "top": 689, "height": 23, "left": 903}, "words": "75"}, {"probability": {"variance": 0.000945, "average": 0.972198, "min": 0.901425}, "location": {"width": 147, "top": 720, "height": 20, "left": 585}, "words": "500≥N)1.000"}, {"probability": {"variance": 1.7e-05, "average": 0.994942, "min": 0.990851}, "location": {"width": 22, "top": 724, "height": 20, "left": 902}, "words": "50"}, {"probability": {"variance": 0.003031, "average": 0.965521, "min": 0.833075}, "location": {"width": 84, "top": 753, "height": 22, "left": 599}, "words": "N≤1.000"}, {"probability": {"variance": 0, "average": 0.999873, "min": 0.999757}, "location": {"width": 85, "top": 755, "height": 25, "left": 873}, "words": "推迟治疗"}, {"probability": {"variance": 0.006907, "average": 0.975197, "min": 0.588363}, "location": {"width": 800, "top": 778, "height": 39, "left": 243}, "words": "4.建议从诱导治疗开始和维持治疗开始之间,推荐的间隔期是8周,每两次维持治疗周"}, {"probability": {"variance": 0.019291, "average": 0.951652, "min": 0.535007}, "location": {"width": 224, "top": 812, "height": 27, "left": 197}, "words": "期之间,问隔期是3周"}, {"probability": {"variance": 0.005877, "average": 0.952206, "min": 0.688042}, "location": {"width": 804, "top": 843, "height": 38, "left": 238}, "words": "5.只有在血小板计数和/或粒性白细胞计数分别达到10,000m3和2.00/m时,才"}, {"probability": {"variance": 0.000133, "average": 0.994971, "min": 0.964594}, "location": {"width": 180, "top": 877, "height": 26, "left": 196}, "words": "考虑进行维持治疗"}, {"probability": {"variance": 0.03528, "average": 0.808846, "min": 0.621017}, "location": {"width": 106, "top": 881, "height": 42, "left": 602}, "words": "制药"}, {"probability": {"variance": 0.003653, "average": 0.983012, "min": 0.716305}, "location": {"width": 438, "top": 910, "height": 32, "left": 238}, "words": "6.建议在诱导及其后治疗期间进行肝功能检查"}, {"probability": {"variance": 0, "average": 0.800699, "min": 0.800699}, "location": {"width": 38, "top": 901, "height": 36, "left": 701}, "words": "交"}, {"probability": {"variance": 0.004439, "average": 0.97917, "min": 0.6226}, "location": {"width": 807, "top": 941, "height": 39, "left": 236}, "words": "7.配制的溶液应避免接触皮肤和粘膜,以及任何药物溶液吸收的可能性,建议配制溶液"}, {"probability": {"variance": 0.007922, "average": 0.977786, "min": 0.561179}, "location": {"width": 563, "top": 975, "height": 32, "left": 192}, "words": "时戴口罩和保护手套,如果意外溅出用水彻底冲洗。"}, {"probability": {"variance": 0.00395, "average": 0.974777, "min": 0.726191}, "location": {"width": 510, "top": 1008, "height": 31, "left": 235}, "words": "8.污染的物品应在保证安全的条件下子以废弃。"}, {"probability": {"variance": 0.019951, "average": 0.925074, "min": 0.396421}, "location": {"width": 479, "top": 1040, "height": 34, "left": 214}, "words": "妊娠及哺乳期妇女用药1本品在孕期及乳期禁用"}, {"probability": {"variance": 1e-05, "average": 0.997803, "min": 0.988826}, "location": {"width": 455, "top": 1073, "height": 32, "left": 196}, "words": "【儿童用药】未进行该项实验且无可靠参考文献"}, {"probability": {"variance": 1.8e-05, "average": 0.997048, "min": 0.983284}, "location": {"width": 455, "top": 1105, "height": 34, "left": 196}, "words": "【老年用药】未进行该项实验且无可靠参考文献"}, {"probability": {"variance": 4e-06, "average": 0.998264, "min": 0.993945}, "location": {"width": 172, "top": 1138, "height": 30, "left": 195}, "words": "药物相互作用】"}, {"probability": {"variance": 7e-06, "average": 0.998235, "min": 0.990155}, "location": {"width": 351, "top": 1174, "height": 25, "left": 235}, "words": "与所有细胞毒药物有相同的相互作用"}, {"probability": {"variance": 0.000185, "average": 0.996128, "min": 0.91905}, "location": {"width": 806, "top": 1207, "height": 30, "left": 231}, "words": "1.因为肿瘤增加了血栓的危险,通常采用抗凝血治疗。肿瘤病例中血液凝固性存在很大"}, {"probability": {"variance": 0.001451, "average": 0.992518, "min": 0.755364}, "location": {"width": 848, "top": 1238, "height": 34, "left": 188}, "words": "的个体间差异,从而增加了口服抗凝血剂与抗肿瘤化疗之间相互作用的不测事件。因此,如"}, {"probability": {"variance": 0.000737, "average": 0.993639, "min": 0.858224}, "location": {"width": 547, "top": 1270, "height": 33, "left": 187}, "words": "若决定患者口服抗凝血剂治疗,需要增加INR检验的次数"}, {"probability": {"variance": 0.001472, "average": 0.984408, "min": 0.882949}, "location": {"width": 161, "top": 1305, "height": 26, "left": 229}, "words": "2.联合用药禁忌"}, {"probability": {"variance": 4e-06, "average": 0.998218, "min": 0.991462}, "location": {"width": 546, "top": 1338, "height": 28, "left": 258}, "words": "1)苯妥英(为了预防某些抗肿瘤药物诱发的惊阙时应用)"}, {"probability": {"variance": 1.7e-05, "average": 0.998396, "min": 0.975485}, "location": {"width": 781, "top": 1370, "height": 33, "left": 254}, "words": "应用阿霉素、柔红霉素、卡铂、顺铂、卡莫司汀、长春新碱、长春碱、博来霉素、甲"}, {"probability": {"variance": 3.7e-05, "average": 0.997358, "min": 0.969984}, "location": {"width": 781, "top": 1403, "height": 32, "left": 254}, "words": "氨蝶呤时,由于细胞增殖抑制剂导致苯妥英在消化道吸收的减少,从而诱发惊阙的发"}, {"probability": {"variance": 2.6e-05, "average": 0.997463, "min": 0.980464}, "location": {"width": 413, "top": 1438, "height": 26, "left": 256}, "words": "作。可短时间与抗惊厥的苯二氮卓类药合用"}, {"probability": {"variance": 0.000118, "average": 0.995761, "min": 0.953281}, "location": {"width": 443, "top": 1470, "height": 29, "left": 256}, "words": "2)黄热病疫苗引致广泛致命的疫苗疾病的危险"}, {"probability": {"variance": 0.003749, "average": 0.977542, "min": 0.804368}, "location": {"width": 185, "top": 1503, "height": 26, "left": 227}, "words": "3.联合用药需考虑"}, {"probability": {"variance": 0.004334, "average": 0.982664, "min": 0.613114}, "location": {"width": 754, "top": 1535, "height": 30, "left": 279}, "words": "1)环孢菌素(阿霉素、依托泊甙);可能有过度的免疫抑制,导致淋巴组织增生"}, {"probability": {"variance": 2e-06, "average": 0.998892, "min": 0.996539}, "location": {"width": 90, "top": 1568, "height": 25, "left": 314}, "words": "的危险性"}, {"probability": {"variance": 0.003871, "average": 0.981403, "min": 0.645229}, "location": {"width": 716, "top": 1602, "height": 26, "left": 313}, "words": "免疫抑制剂(由环孢菌素外推法得出):过度的免疫抑制,导致淋巴细胞增生"}], "language": 3}